Alzamend Neuro, Inc.
ALZN
$0.7672
-$0.0028-0.36%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/8/2025
-
Zacks Investment Research
3/29/2025
-
Ticker Report
3/28/2025
-
Insider Monkey
3/28/2025
-
Yahoo! Finance: News
3/25/2025
-
Insider Monkey
3/25/2025
-
GuruFocus
3/25/2025
-
The Fly
3/25/2025
-
Globe Newswire
3/18/2025
-
GuruFocus
3/18/2025
-
The Fly
3/18/2025
-
Globe Newswire
3/13/2025
-
TipRanks Financial Blog
3/13/2025
-
The Fly
3/12/2025
-
Ticker Report
3/11/2025
-
GuruFocus
3/11/2025
-
TipRanks Financial Blog
3/11/2025
-
The Fly
3/11/2025
-
Globe Newswire
3/4/2025
-
GuruFocus
3/4/2025
-
The Fly
3/4/2025
-
Globe Newswire
2/25/2025
-
GuruFocus
2/25/2025
-
The Fly
2/25/2025
-
Globe Newswire
2/25/2025
-
Benzinga
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 10, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
End of July (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
844 722 6333
Address
3480 Peachtree Road NE
Atlanta, GA 30326
Atlanta, GA 30326
Country
Year Founded
Business Description
Sector
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes...
more
